Jane Theaker

Jane Theaker has a BSc (Hons) in Biochemistry from Manchester University and an MSc in Biomedical Science from Manchester Metropolitan University. She has over 25 years of experience in Diagnostics and Pharma, having co-invented a technology that was later spun out to create DxS which was acquired by QIAGEN in 2009 for $130M. She trained in the NHS and worked at AstraZeneca evaluating novel genetic technologies for drug discovery and development. At QIAGEN she lead a team of scientists who were responsible for the successful delivery of several FDA-approved companion diagnostic products and went on to head up the technology office, with technology horizon-scanning responsibilities. Jane went on to become VP of Genomics at LGC (the Laboratory of the Government Chemist) in 2015. Jane is currently CEO of Kinomica Ltd with a number of shares in ArcticZymes Technologies held by Mrs. Theaker: 0.